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Abstract
The seven-valent pneumococcal conjugate vaccine (PCV7) has been available in Portugal since June 2001, but is not included in the
National Vaccination Plan. Its impact on colonization is unknown. A point-prevalence study to evaluate PCV7 usage was carried out in
2006 among day-care centre attendees from the Lisbon area. Pneumococcal carriage rates, serotypes, and antibiotypes were determined
and compared with results from a similar study conducted in 2001 before vaccine approval. In 2001 and 2006, 717 and 571 children,
respectively, were enrolled. In 2006, 45.9% of the participants were appropriately vaccinated and 11.5% were incompletely vaccinated.
Carriage of pneumococci remained stable (64.9% in 2001; 68.7% in 2006). Vaccine types (VT) decreased from 53.1% of all pneumococci
to 11.2% (p <0.001). Serotype replacement was observed among vaccinated and unvaccinated children. Non-vaccine types (NVT) 1, 6C,
7F, 15A, 16F, 21, 23A, 29, and non-typeable (NT) strains increased signiﬁcantly; serotype 19A increased, but not signiﬁcantly. Rates of
resistance to penicillin, erythromycin, clindamycin and tetracycline remained stable (p >0.05) due to signiﬁcant increases in intermediate
resistance to penicillin (from 5.5% to 17.8%), erythromycin (from 9.2% to 21.8%), clindamycin (from 6.4% to 19.3%) and tetracycline
(from 8.3% to 15.8%) among NVT. Whereas in 2001 resistance among NVT was mostly associated with serotype 19A and NT strains,
in 2006 resistance was also found among serotypes 6C, 15A, 24F and 33F. In conclusion, dramatic shifts in serotypes of colonizing pneu-
mococci were observed among vaccinated and unvaccinated children. Rates of antibiotic resistance remained unchanged due to a bal-
ance between reduction in VT and an increase in antimicrobial-resistant NVT.
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Introduction
Pneumococcal infections remain a leading cause of morbidity
and mortality worldwide. Infection is preceded by coloniza-
tion of the nasopharynx. In most individuals colonization is
asymptomatic and does not evolve into disease. The carrier
state is more frequent in young children and may reach >70%
in some settings such as day-care centres (reviewed in [1]).
Children attending day-care centres have been found to
be major reservoirs of pneumococci, playing a key role in
the ampliﬁcation of the ﬁttest pneumococcal lineages [2,3]
and contributing signiﬁcantly to pneumococcal transmission
to other individuals [4,5].
According to the Ministry of Education, between 2002 and
2004, over 75% of pre-school children living in Portugal
attended day-care centres [6]. These high attendance levels
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02775.x
result from relatively short maternity leave periods (4–5
months) and economic and cultural situations that often lead
both parents to work full time. Colonization studies carried
out in the late 1990s among day-care centre attendees
in Portugal have documented high carriage rates of pneumo-
cocci that have exceeded 60% [7].
Furthermore, a signiﬁcant proportion of the isolates was
reported to be resistant to antibiotics (c. 40%). The rate of
non-susceptibility to penicillin, resistance to macrolides and
tetracycline, and multidrug resistance was in the range of
20–25%. By using serotyping and molecular typing
approaches, it was shown that the majority of drug-resistant
isolates belonged to a few internationally disseminated
clones, most of which expressed serotypes 6B, 9V, 14, 19F
and 23F [3,7,8].
The seven-valent pneumococcal conjugate vaccine
(PCV7, targeting serotypes 4, 6B, 9V, 14, 18C, 19F and
23F) has been introduced in the universal immunization
programme of the USA in 2000. Its impact on the inci-
dence of invasive pneumococcal disease has been signiﬁ-
cant not only in infants but also among older children and
adults [9]. Furthermore, since ﬁve PCV7 serotypes (6B,
9V, 14, 19F and 23F) are frequently associated with peni-
cillin, macrolide and multidrug resistance, an added antici-
pated beneﬁt of the vaccine was a decrease in rates of
antimicrobial resistance, which, in fact, has been observed
among invasive disease isolates [10].
In Portugal, PCV7 has been available in the market since
June 2001. In 2003, the Portuguese Paediatric Society recom-
mended its universal use in children under 2 years of age
[11]. However, as of July 2008, the vaccine has not been
included in the National Vaccination Plan and is not subsi-
dized by the state. The vaccine is given solely under medical
prescription.
Studies on the impact of PCV7 use in pneumococcal
colonization in Portugal are non-existent except for a sin-
gle controlled study, conducted by our group from 2001
to 2003, on the impact of PCV7 on antibiotic-resistant
colonizing pneumococci in a cohort of day-care centre
attendees [12]. In that study, following PCV7 vaccination,
serotype replacement was observed in the vaccinated
group, but antimicrobial resistance levels remained high
and unchanged.
To evaluate PCV7 use in Portugal and determine its
impact in pneumococcal colonization, we compared results
of carriage rates, serotypes, and antibiotypes obtained in two
point-prevalence studies carried out among day-care centre
attendees from Lisbon and Oeiras in 2001 (a few months
before vaccine approval) and 5 years later.
Materials and Methods
Study design
The study was conducted in Lisbon and Oeiras (two geogra-
phically close urban areas) in the winter months of January–
March of 2001 (pre-vaccination era in Portugal) and 2006
(vaccination era). The target population was preschool chil-
dren aged 4 months to 6 years attending day-care centres.
Day-care centres were selected to cover the spectrum of
social backgrounds found in the area. In 2001 the target popu-
lation was 1061 children attending 11 day-care centres and
in 2006 corresponding ﬁgures were 908 children attending
12 day-care centres. Seven day-care centres were common to
both studies. For each child one nasopharyngeal sample was
obtained and a questionnaire was ﬁlled in as detailed below.
Approval for the study was obtained from the Ministry of
Education and Directors of day-care centres. Signed
informed consent was obtained from the parents or guard-
ians of participating children.
Nasopharyngeal sampling and pneumococcal isolation
Specimen collection, transport, isolation, identiﬁcation of
pneumococci and preparation of frozen stocks were done by
routine procedures previously described [2,3].
Serotyping
Isolates were serotyped by multiplex PCR as previously
described [13] or, for those isolates for which the serotype
could not be determined by this method, the Quellung reaction
with speciﬁc antisera was used (Statens Serum Institut, Copen-
hagen, Denmark). Distinction between serotypes 6A and 6C
was done by PCR using the primers proposed by Park et al.
[14]. Capsular types targeted by PCV7 (4, 6B, 9V, 14, 18C, 19F
and 23F) were classiﬁed as vaccine-types (VT). All other types
were classiﬁed as non-vaccine types (NVT). Serotypes of drug-
resistant strains isolated in 2001 have been reported [15].
Antimicrobial susceptibility testing
Isolates were tested for susceptibility to erythromycin,
clindamycin, tetracycline, chloramphenicol, sulfamethoxazole-
trimethoprim (SXT), and levoﬂoxacin by disk-diffusion
following the CLSI guidelines and interpretive criteria [16].
Testing of susceptibility to penicillin, amoxicillin, and ceftriax-
one was done by Etest (AB Biodisk, Solna, Sweden)
according to the manufacturer’s instructions. Interpretation
was done using the following CLSI recommended break-
points (MIC in mg/L) [16]: for penicillin (oral penicillin V) the
criteria used were £0.06, 0.12–1 and ‡2 for classiﬁcation of
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susceptibility, intermediate resistance and resistance, respec-
tively. Breakpoints for amoxicillin (non-meningitis) were £2,
4 and ‡8 and for ceftriaxone (non-meningitis) were £1, 2
and ‡4, respectively. Antibiotypes of strains isolated in 2001
have been reported [15].
Questionnaires
Information regarding age, gender, recent antimicrobial con-
sumption, reason for antimicrobial use and PCV7 vaccination
was obtained.
Interpretation of vaccination status
Children enrolled in 2001 were classiﬁed as non-vaccinated
as PCV7 was unavailable in Portugal at the time of surveil-
lance. Children enrolled in 2006 were grouped in mutually
exclusive categories as detailed in Table S1.
Statistical analysis
Proportional differences in children’s colonization per sero-
type were analysed with v2 test or Fisher’s exact test where
appropriate. Differences in children’s mean ages were
detected by a two-tailed t-test. A p-value of <0.05 was con-
sidered statistically signiﬁcant. The 95% CI for any propor-
tion was calculated with the Wilson score interval. All
statistical analyses were performed with R, version 2.60 [17].
Results
Demographic data and antimicrobial use
The number of children enrolled was 717 in 2001 and 571 in
2006, corresponding to a participation of 68% and 63%,
respectively, of the target population. Table 1 shows the
demographic characteristics of the two populations, which
were similar in age and gender distribution.
Antimicrobial use in the month preceding the sampling
was high—23.7% in 2001 and 19.3% in 2006—and did not
differ signiﬁcantly between the two study periods. Patterns
of antimicrobial use were comparable. Antibiotics most fre-
quently prescribed were amoxicillin/clavulanic acid (41.1% in
2001 and 33.3% in 2006), amoxicillin (21.7% and 24.7%),
macrolides (16.3% and 16.1%), and second-generation cepha-
losporins (12.4% and 15.1%).
Repeated antimicrobial use, deﬁned as three or more
courses of antimicrobials in the 6 months preceding the sam-
pling, was signiﬁcantly lower in 2006 (15.6%) compared with
2001 (24.5%, p 0.005).
Use of PCV7
In 2006 57.4% of children had received at least one dose of
the vaccine and 45.9% were age-appropriately vaccinated.
Use of PCV7 was higher among the youngest, ranging from
81.0% among children aged 1 year to 42.9% among children
aged 6 years.
Carriage of pneumococci and serotype replacement
Carriage of pneumococci was high and comparable: 64.9% in
2001 and 68.7% in 2006. VT decreased from 53.1% of all pneu-
mococcal isolates obtained in 2001 to 11.2% in 2006
(p <0.001); NVT increased from 46.9% in 2001 to 88.8% in
2006 (p <0.001). This serotype replacement phenomenon was
observed among vaccinated and unvaccinated children (Fig. 1).
TABLE 1. Characteristics of the populations
Characteristic 2001, N = 717 (%) 2006, N = 571 (%) p
Age, year, mean (SD) 3.97 (1.48) 4.01 (1.43) 0.328
4 months to <1 year 30 (4.2) 24 (4.2)
1–<2 years 60 (8.4) 42 (7.4)
2–<3 years 102 (14.2) 60 (10.5)
3–<4 years 115 (16.0) 124 (21.7)
4–<5 years 182 (25.4) 143 (25.0)
5–<6 years 204 (28.5) 164 (28.7)
6 years 24 (3.3) 14 (2.5)
Males 365 (50.9) 292 (51.1) 0.979
Use of antibiotics
Recent (last month)a 146 (23.7) 101 (19.3) 0.254
Repeated (‡3 last 6 months)b 148 (24.5) 83 (15.6) 0.005
Carriage of pneumococci 465 (64.9) 392 (68.7) 0.169
Missing data for 2006: n = 1 age 4 months–<1 year, n = 4 age 1–<2 years, n = 2
age 2–<3 years, n = 10 age 3–<4 years, n = 11 age 4–<5 years, n = 26 age 5–
<6 years, n = 2 age 6 years.
aMissing data: n = 102 for 2001, n = 47 for 2006 (analysis conducted with avail-
able data).
bMissing data: n = 114 for 2001, n = 38 for 2006 (analysis conducted with avail-
able data).
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FIG. 1. Pneumococcal carriage patterns in two study periods. Dark
blocks, samples containing vaccine type pneumococci; white blocks,
samples containing non-vaccine type pneumococci. p values refer to
comparison with 2001.
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Changes in serotype distribution
All VT decreased in abundance from 2001 to 2006 (Fig. 2).
Although NVT, as a whole, increased in abundance, replacing
VT, analysis by individual serotype showed different dynamics.
In particular, signiﬁcant increases were observed for serotypes
6C, 7F, 16F, 21, 23A and 29 (Fig. 2). All these serotypes repre-
sented only 0.2–0.9% of the isolates in 2001, but their relative
abundance in 2006 increased several fold (2.8–5.9%). Non-
typeable isolates also increased signiﬁcantly/from 1.5% in 2001
to 5.1% in 2006. In addition, serotypes 1 and 15A, which were
not isolated in 2001, were detected in 3.3% and 5.1%, respec-
tively, of all pneumococci isolated in 2006. All the above-men-
tioned NVT were detected among vaccinated and
unvaccinated children from a diverse group of day-care cen-
tres, suggesting that their increase and/or emergence was not
conﬁned to a cross-transmission event within a single institu-
tion. The remaining NVT, including the abundant serotypes 6A
and 19A, did not change signiﬁcantly (Fig. 2).
Antimicrobial resistance
Non-susceptibility to penicillin (using oral penicillin V crite-
ria) did not change signiﬁcantly from 2001 to 2006
(Table 2), but a decline in MIC90 values was observed, from
1 to 0.25 mg/L. All isolates were susceptible to amoxicillin
and ceftriaxone (using non-meningitis criteria), and a decline
in MIC90 values was observed, from 0.5 to 0.12 mg/L, and
0.5 to 0.25 mg/L, respectively. MICs of amoxicillin were
identical to or lower than those of penicillin with the single
exception of a non-typeable isolate obtained in 2006 for
which MICs of penicillin and amoxicillin were 1 and 2 mg/L,
respectively.
The rates of resistance to erythromycin and tetracycline
did not show a signiﬁcant change, but resistance to SXT and
chloramphenicol decreased signiﬁcantly (p <0.001).
In 2001, rates of resistance to all antibiotics were substan-
tially lower among NVT compared with VT. Although this was
still true in 2006, signiﬁcant increases in intermediate resis-
tance to penicillin (MIC of 0.12–1 mg/L, from 5.5% to 17.8%),
erythromycin (from 9.2% to 21.8%), clindamycin (from 6.4% to
19.3%) and tetracycline (from 8.3% to 15.8%) were observed
among NVT. This increase in resistance, together with the
serotype replacement phenomenon, led to the global mainte-
nance of antimicrobial resistance rates to penicillin, erythro-
mycin, clindamycin and tetracycline. Rates of multidrug
resistance, deﬁned as resistance to three or more antibiotics,
were also comparable (24.5% in 2001, 20.4% in 2006, p 0.177).
NVT associated with antibiotic resistance
In 2001, resistance among NVT was almost exclusively due
to the presence of serotype 19A and non-typeable isolates
exhibiting intermediate resistance to penicillin and resistance
to macrolides and tetracycline (a single drug-resistant
serotype 3 isolate was also obtained). In 2006, antibiotic-
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FIG. 2. Changes in the abundance of vaccine
type (VT) and non-vaccine type (NVT). White
bars, 2001; grey bars, 2006. The 206 NVTs
labelled ‘other’ include, 9A, 18A, 18B, 18F and
38.
TABLE 2. Antimicrobial resistance rates in 2001 and 2006
Antimicrobial
2001 (n = 465) 2006 (n = 392)
S I R S I R
Penicillin 76.3 21.5 2.2 78.0 20.2 1.8
Amoxicillin 100.0 0.0 0.0 100.0 0.0 0.0
Ceftriaxone 100.0 0.0 0.0 100.0 0.0 0.0
Erythromycin 73.8 0.0 26.2 76.2 0.3 23.5
Clindamycin 79.0 0.4 20.6 79.3 0.5 20.2
Tetracycline 77.0 0.6 22.4 81.6 1.3 17.1
SXT 74.4 1.9 23.7 88.0 1.0 11.0
Chloramphenicol 92.5 0.0 7.5 99.7 0.0 0.3
Levoﬂoxacin 100.0 0.0 0.0 100.0 0.0 0.0
Multidrug resistance – – 24.5 – – 20.4
Values indicate percentage of all pneumococci. Strains resistant to penicillin had
an MIC of 2 lg/mL. Multidrug resistance was deﬁned as resistance to three or
more antibiotics.
S, susceptible; I, intermediate; R, resistant; SXT, sulfamethoxazole-trimethoprim.
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resistant serotype 19A and non-typeable isolates were still in
circulation, but isolates of other NVT—6C, 15A, 24F and
33F—also exhibited resistant phenotypes. There was no sig-
niﬁcant evidence that resistance within the individual NVT
might have increased.
Discussion
This is the ﬁrst study from Portugal that aimed to evaluate
PCV7 use and its impact on pneumococcal colonization, ser-
otypes and antimicrobial resistance rates. The ﬁrst important
observation is that use of PCV7 is very high despite the fact
that it is neither included in the National Vaccination Plan
nor subsidized by the state. Nonetheless, as many as 57.4%
of the children enrolled in 2006 had received at least one
dose of the vaccine and 45.9% were age-appropriately vacci-
nated. The fact that PCV7 is expensive (the cost of four
doses is equivalent to 70% of the national minimum monthly
wage) does not seem to impede its acquisition, suggesting
that Portuguese paediatricians are frequently prescribing
PVC7, which parents are willing to pay for.
The second important observation is that, although no sig-
niﬁcant changes in pneumococcal carriage rates were
observed, major shifts in the abundance of VT (from 53.1%
to 11.2% of all isolates) and NVT (from 46.9% to 88.8%)
have occurred among vaccinated and non-vaccinated chil-
dren. Our observations indicate that in this population PCV7
vaccination has reached a coverage level sufﬁciently high to
promote an indirect herd effect on non-vaccinees, also
reported in other populations [18].
According to this study, all VT detected in 2001
decreased signiﬁcantly in their abundance. In the case of
NVT, 22 of the 24 serotypes detected in 2001 were also iso-
lated in 2006 and, in addition, ‘novel’ NVT (i.e. serotypes 1,
9A, 15A, 18F, 33F and 38) were detected in 2006.
Among NVT serotypes 6C, 7F, 16F, 21, 23A, 29 and non-
typeable isolates increased signiﬁcantly. The reasons for such
variations are probably complex, depending on several factors
such as secular trends, epidemics, introduction and dissemina-
tion of novel clones, unmasking effects due to competition
among serotypes or other yet unidentiﬁed selective forces
[19,20]. Given that the NVT that increased signiﬁcantly or
‘emerged’ in 2006 were mostly susceptible to all antibiotics,
their increase was not driven by antibiotic pressure.
As the data obtained in this study relate to only two time
points 5 years apart, the importance of the most dramatic
serotype shifts is not clear. Still, it is of interest to note that, as
in our study, after introduction of PCV7 an increase in sero-
type 16F was noted among young Australian aboriginal
children [21], and an increase in serogroups/types 15, 23A and
29 has been described in Massachusetts [22]. Although sero-
type 19A increased in our study, it was not statistically signiﬁ-
cant. In contrast with other studies, there was no decline in
serotype 6A [22,23]. Serotype 6C increased signiﬁcantly.
A signiﬁcant increase in serotypes 1 and 7F, known for
being able to cause outbreaks of invasive disease, especially
meningitis, and to be poor colonizers [24], was also
observed. For serotype 1, we recently showed that all iso-
lates belong to a single clone that is circulating in Europe
[25]. Whether the observed increase in serotypes 1 and 7F
results from an epidemic, was triggered by introduction of
PCV7, or, at least, was enhanced by it, is currently unclear.
One of the most important observations of this study was
that the rates of antimicrobial resistance to penicillin (non-
susceptibility), macrolides, tetracycline and multidrug resis-
tance in general have not changed signiﬁcantly despite the
sharp decline of VT. An important increase in antimicrobial
resistance among NVT has occurred, and whether this is a
continuous trend or whether an equilibrium has been
reached is currently unknown.
Outpatient antibiotic consumption in Portugal remains one
of the highest in Europe [26] and evidence of a direct correla-
tion between high antimicrobial use and increased prevalence
of antimicrobial-resistant pneumococci has been obtained [27].
In this study, although there was a decline in antibiotic use, it
remained high. Our observations seem to indicate that the
selective pressure for antimicrobial resistance due to high anti-
microbial consumption remains a major driving force for main-
tenance, expansion and emergence of resistant strains [26].
In summary, in Portugal, a developed country with med-
ium levels of resistance among pneumococci, high antimicro-
bial use and high use of PCV7, a dramatic shift in the
serotypes colonizing the children attending day-care centres
in the Lisbon area has been observed among vaccinated and
unvaccinated children. Rates of intermediate resistance to
penicillin and resistance to macrolides, tetracycline and multi-
drug resistance have remained unchanged due to a balance
between reduction in VT and an increase in antimicrobial
resistance among NVT. In the years to come, further surveil-
lance studies and approaches are needed to understand fully
the impact of conjugate vaccines on pneumococcal ecology
in general and on antimicrobial resistance in particular and to
explore their different implications for disease.
Acknowledgements
The authors are grateful to the Director and staff of the day-
care centres and the parents and children who collaborated
1006 Clinical Microbiology and Infection, Volume 15 Number 11, November 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1002–1007
in the study. We thank R. Mato, N. Sousa and C. Simas, for
participating in studies that led to the isolation of strains in
2001 and acknowledge the excellent skills of the paediatric
nurse A. Gonc¸alves, who collected the nasopharyngeal
samples.
Transparency Declaration
This work was supported by projects EURIS (contract
QKL2-CT-2000-01020), PREVIS (LSHM-CT-2003-503413),
and GRACE (contract PL518226) from the European Com-
mission and project PDTC/SAU-ESA/64888/2006 and Finan-
ciamento Base 2008—ISFL/1/209 from Fundac¸a˜o para a
Cieˆncia e Tecnologia, Portugal. The authors declare that they
have no conﬂicts of interest.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Criteria used to determine whether a child
was age-appropriately vaccinated with PCV7.
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
References
1. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae col-
onisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4:
144–154.
2. Sa´-Lea˜o R, Nunes S, Brito-Avoˆ A et al. High rates of transmission of
and colonization by Streptococcus pneumoniae and Haemophilus inﬂuen-
zae within a day care center revealed in a longitudinal study. J Clin
Microbiol 2008; 46: 225–234.
3. Sa´-Lea˜o R, Tomasz A, Sanches IS et al. Carriage of internationally
spread clones of Streptococcus pneumoniae with unusual drug resis-
tance patterns in children attending day care centers in Lisbon, Por-
tugal. J Infect Dis 2000; 182: 1153–1160.
4. Huang SS, Finkelstein JA, Lipsitch M. Modeling community- and indi-
vidual-level effects of child-care center attendance on pneumococcal
carriage. Clin Infect Dis 2005; 40: 1215–1222.
5. Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive
pneumococcal disease. N Engl J Med 2000; 342: 681–689.
6. Ministry of Education. Educac¸a˜o pre´-escolar – Evoluc¸a˜o do nu´mero de cri-
anc¸as (de 1998/1999 a 2003/2004). Portugal:Ministry of Education, 2007.
7. Nunes S, Sa´-Lea˜o R, Carric¸o J et al. Trends in drug resistance, sero-
types, and molecular types of Streptococcus pneumoniae colonizing
preschool-age children attending day care centers in Lisbon, Portugal:
a summary of 4 years of annual surveillance. J Clin Microbiol 2005; 43:
1285–1293.
8. Sa´-Lea˜o R, Tomasz A, de Lencastre H. Multilocus sequence typing
of Streptococcus pneumoniae clones with unusual drug resistance
patterns: genetic backgrounds and relatedness to other epidemic
clones. J Infect Dis 2001; 184: 1206–1210.
9. Reynold A, Farley M, Harrison L et al. Direct and indirect effects of
routine vaccination of children with 7-valent pneumococcal conjugate
vaccine on incidence of invasive pneumococcal disease-United States,
1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893–897.
10. Kyaw MH, Lynﬁeld R, Schaffner W et al. Effect of introduction of the
pneumococcal conjugate vaccine on drug-resistant Streptococcus pneu-
moniae. N Engl J Med 2006; 354: 1455–1463.
11. Secc¸a˜o-de-Infecciologia-Pedia´trica-da-Sociedade-Portuguesa-de-Pediat-
ria. Recomendac¸o˜es das Secc¸o˜es. Vacinas conjugadas contra Neisseria
meningitidis C e Streptococcus pneumoniae. Acta Pediatr Port 2003; 34:
373–375.
12. Fraza˜o N, Brito-Avoˆ A, Simas C et al. Effect of the seven-valent con-
jugate pneumococcal vaccine on carriage and drug resistance of Strep-
tococcus pneumoniae in healthy children attending day-care centers in
Lisbon. Pediatr Infect Dis J 2005; 24: 243–252.
13. Brito DA, Ramirez M, de Lencastre H. Serotyping Streptococcus pneu-
moniae by multiplex PCR. J Clin Microbiol 2003; 41: 2378–2384.
14. Park IH, Park S, Hollingshead SK, Nahm MH. Genetic basis for the
new pneumococcal serotype, 6C. Infect Immun 2007; 75: 4482–4489.
15. Mato R, Sanches IS, Simas C et al. Natural history of drug-resistant
clones of Streptococcus pneumoniae colonizing healthy children in Por-
tugal. Microb Drug Resist 2005; 11: 309–322.
16. CLSI. Performance standards for antimicrobial disk susceptibility tests;
approved standard, 9th edn. Wayne, PA: CLSI publication M2-A9. Clin-
ical and Laboratory Standards Institute, 2007.
17. R Development Core Team. R: a language and environment for statisti-
cal computing. Vienna, Austria: R Foundation for Statistical Computing,
2007.
18. O’Brien KL, Dagan R. The potential indirect effect of conjugate pneu-
mococcal vaccines. Vaccine 2003; 21: 1815–1825.
19. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from
Haemophilus inﬂuenzae and prospects for Streptococcus pneumoniae.
Emerg Infect Dis 1999; 5: 336–345.
20. Lipsitch M, Dykes JK, Johnson SE et al. Competition among Strepto-
coccus pneumoniae for intranasal colonization in a mouse model. Vac-
cine 2000; 18: 2895–2901.
21. Marsh RL, Smith-Vaughan H, Beissbarth J et al. Molecular characteri-
sation of pneumococcal serotype 16F: established predominant car-
riage and otitis media serotype in the 7vPCV era. Vaccine 2007; 25:
2434–2436.
22. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkel-
stein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in
16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116:
e408–e413.
23. Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal
carriage of Streptococcus pneumoniae after administration of a 9-valent
pneumococcal conjugate vaccine to toddlers attending day care cen-
ters. J Infect Dis 2002; 185: 927–936.
24. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in pae-
diatric invasive disease. Vaccine 2007; 25: 2406–2412.
25. Nunes S, Sa´-Lea˜o R, Pereira LC, Lencastre H. Emergence of a sero-
type 1 Streptococcus pneumoniae lineage colonising healthy children in
Portugal in the seven-valent conjugate vaccination era. Clin Microbiol
Infect 2008; 14: 82–84.
26. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance
of Antimicrobial Consumption (ESAC): outpatient antibiotic use in
Europe. J Antimicrob Chemother 2006; 58: 401–407.
27. Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in
Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J
Clin Microbiol Infect Dis 2007; 26: 485–490.
CMI Sa´-Lea˜o et al. Changes in pneumococci after PCV7 use in Portugal 1007
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1002–1007
